2007-05-18
AUTHORS ABSTRACTOpinion statementFibromuscular dysplasia (FMD) and aortoarteritis are the most frequent causes of secondary hypertension induced by renal artery stenosis (RAS). Revascularization of this disease entity usually cures arterial hypertension. Demographic evolution leads to an increasing incidence of atherosclerotic RAS, one of the major causes of end-stage renal failure. Furthermore, atherosclerotic RAS leads to deterioration of primary hypertension, progression of atherosclerosis manifestation such as occlusive and aneurysmatic peripheral artery disease, and chronic or acute organ damage such as left ventricular hypertrophy and recurrent flash pulmonary edema. Despite the lack of sufficiently powered randomized controlled trials, each hemodynamically relevant RAS (eg, ≥ 70%) should be considered for stent angioplasty in patients without end-stage ischemic nephropathy or limited life expectancy due to concomitant disease (eg, cancer). Drug-eluting stents will probably reduce the overall low in-stent restenosis rate of 10% to 20%. Interventions in patients with dialysis-dependent end-stage nephropathy are left to appropriate clinical study protocols. More... »
PAGES90-98
http://scigraph.springernature.com/pub.10.1007/s11936-007-0002-9
DOIhttp://dx.doi.org/10.1007/s11936-007-0002-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1025547914
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/17484811
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Abteilung Angiologie, Herz-Zentrum Bad Krozingen, S\u00fcdring 15, D-79189, Bad Krozingen, Germany",
"id": "http://www.grid.ac/institutes/grid.418466.9",
"name": [
"Abteilung Angiologie, Herz-Zentrum Bad Krozingen, S\u00fcdring 15, D-79189, Bad Krozingen, Germany"
],
"type": "Organization"
},
"familyName": "Zeller",
"givenName": "Thomas",
"id": "sg:person.01306206724.74",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306206724.74"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s003300050707",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1039905631",
"https://doi.org/10.1007/s003300050707"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.jhh.1000599",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018663291",
"https://doi.org/10.1038/sj.jhh.1000599"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/sj.jhh.1001641",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017671862",
"https://doi.org/10.1038/sj.jhh.1001641"
],
"type": "CreativeWork"
}
],
"datePublished": "2007-05-18",
"datePublishedReg": "2007-05-18",
"description": "Opinion statementFibromuscular dysplasia (FMD) and aortoarteritis are the most frequent causes of secondary hypertension induced by renal artery stenosis (RAS). Revascularization of this disease entity usually cures arterial hypertension. Demographic evolution leads to an increasing incidence of atherosclerotic RAS, one of the major causes of end-stage renal failure. Furthermore, atherosclerotic RAS leads to deterioration of primary hypertension, progression of atherosclerosis manifestation such as occlusive and aneurysmatic peripheral artery disease, and chronic or acute organ damage such as left ventricular hypertrophy and recurrent flash pulmonary edema. Despite the lack of sufficiently powered randomized controlled trials, each hemodynamically relevant RAS (eg, \u2265 70%) should be considered for stent angioplasty in patients without end-stage ischemic nephropathy or limited life expectancy due to concomitant disease (eg, cancer). Drug-eluting stents will probably reduce the overall low in-stent restenosis rate of 10% to 20%. Interventions in patients with dialysis-dependent end-stage nephropathy are left to appropriate clinical study protocols.",
"genre": "article",
"id": "sg:pub.10.1007/s11936-007-0002-9",
"inLanguage": "en",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1119516",
"issn": [
"1092-8464",
"1534-3189"
],
"name": "Current Treatment Options in Cardiovascular Medicine",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "9"
}
],
"keywords": [
"renal artery stenosis",
"atherosclerotic renal artery stenosis",
"artery stenosis",
"recurrent flash pulmonary edema",
"end-stage renal failure",
"acute organ damage",
"flash pulmonary edema",
"end-stage nephropathy",
"peripheral artery disease",
"limited life expectancy",
"stent restenosis rate",
"clinical study protocol",
"drug-eluting stents",
"relevant renal artery stenosis",
"atherosclerosis manifestations",
"ischemic nephropathy",
"secondary hypertension",
"arterial hypertension",
"concomitant diseases",
"renal failure",
"primary hypertension",
"artery disease",
"organ damage",
"ventricular hypertrophy",
"restenosis rate",
"pulmonary edema",
"stent angioplasty",
"study protocol",
"disease entity",
"frequent cause",
"hypertension",
"major cause",
"life expectancy",
"nephropathy",
"stenosis",
"patients",
"disease",
"overall low",
"cause",
"aortoarteritis",
"revascularization",
"angioplasty",
"edema",
"dysplasia",
"hypertrophy",
"incidence",
"stents",
"progression",
"trials",
"manifestations",
"intervention",
"expectancy",
"failure",
"damage",
"deterioration",
"entities",
"protocol",
"rate",
"lack",
"low",
"demographic evolution",
"evolution"
],
"name": "Renal artery stenosis",
"pagination": "90-98",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1025547914"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s11936-007-0002-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"17484811"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s11936-007-0002-9",
"https://app.dimensions.ai/details/publication/pub.1025547914"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T09:55",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_437.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s11936-007-0002-9"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11936-007-0002-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11936-007-0002-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11936-007-0002-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11936-007-0002-9'
This table displays all metadata directly associated to this object as RDF triples.
136 TRIPLES
22 PREDICATES
91 URIs
80 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s11936-007-0002-9 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1102 |
3 | ″ | schema:author | Nbd779649f24c4f2ba90ae808bee468b6 |
4 | ″ | schema:citation | sg:pub.10.1007/s003300050707 |
5 | ″ | ″ | sg:pub.10.1038/sj.jhh.1000599 |
6 | ″ | ″ | sg:pub.10.1038/sj.jhh.1001641 |
7 | ″ | schema:datePublished | 2007-05-18 |
8 | ″ | schema:datePublishedReg | 2007-05-18 |
9 | ″ | schema:description | Opinion statementFibromuscular dysplasia (FMD) and aortoarteritis are the most frequent causes of secondary hypertension induced by renal artery stenosis (RAS). Revascularization of this disease entity usually cures arterial hypertension. Demographic evolution leads to an increasing incidence of atherosclerotic RAS, one of the major causes of end-stage renal failure. Furthermore, atherosclerotic RAS leads to deterioration of primary hypertension, progression of atherosclerosis manifestation such as occlusive and aneurysmatic peripheral artery disease, and chronic or acute organ damage such as left ventricular hypertrophy and recurrent flash pulmonary edema. Despite the lack of sufficiently powered randomized controlled trials, each hemodynamically relevant RAS (eg, ≥ 70%) should be considered for stent angioplasty in patients without end-stage ischemic nephropathy or limited life expectancy due to concomitant disease (eg, cancer). Drug-eluting stents will probably reduce the overall low in-stent restenosis rate of 10% to 20%. Interventions in patients with dialysis-dependent end-stage nephropathy are left to appropriate clinical study protocols. |
10 | ″ | schema:genre | article |
11 | ″ | schema:inLanguage | en |
12 | ″ | schema:isAccessibleForFree | false |
13 | ″ | schema:isPartOf | N3fb599378c214e3eaf6b76cf194e5013 |
14 | ″ | ″ | Nf21a054ddd5d44529fa24a72a7ec0c61 |
15 | ″ | ″ | sg:journal.1119516 |
16 | ″ | schema:keywords | acute organ damage |
17 | ″ | ″ | angioplasty |
18 | ″ | ″ | aortoarteritis |
19 | ″ | ″ | arterial hypertension |
20 | ″ | ″ | artery disease |
21 | ″ | ″ | artery stenosis |
22 | ″ | ″ | atherosclerosis manifestations |
23 | ″ | ″ | atherosclerotic renal artery stenosis |
24 | ″ | ″ | cause |
25 | ″ | ″ | clinical study protocol |
26 | ″ | ″ | concomitant diseases |
27 | ″ | ″ | damage |
28 | ″ | ″ | demographic evolution |
29 | ″ | ″ | deterioration |
30 | ″ | ″ | disease |
31 | ″ | ″ | disease entity |
32 | ″ | ″ | drug-eluting stents |
33 | ″ | ″ | dysplasia |
34 | ″ | ″ | edema |
35 | ″ | ″ | end-stage nephropathy |
36 | ″ | ″ | end-stage renal failure |
37 | ″ | ″ | entities |
38 | ″ | ″ | evolution |
39 | ″ | ″ | expectancy |
40 | ″ | ″ | failure |
41 | ″ | ″ | flash pulmonary edema |
42 | ″ | ″ | frequent cause |
43 | ″ | ″ | hypertension |
44 | ″ | ″ | hypertrophy |
45 | ″ | ″ | incidence |
46 | ″ | ″ | intervention |
47 | ″ | ″ | ischemic nephropathy |
48 | ″ | ″ | lack |
49 | ″ | ″ | life expectancy |
50 | ″ | ″ | limited life expectancy |
51 | ″ | ″ | low |
52 | ″ | ″ | major cause |
53 | ″ | ″ | manifestations |
54 | ″ | ″ | nephropathy |
55 | ″ | ″ | organ damage |
56 | ″ | ″ | overall low |
57 | ″ | ″ | patients |
58 | ″ | ″ | peripheral artery disease |
59 | ″ | ″ | primary hypertension |
60 | ″ | ″ | progression |
61 | ″ | ″ | protocol |
62 | ″ | ″ | pulmonary edema |
63 | ″ | ″ | rate |
64 | ″ | ″ | recurrent flash pulmonary edema |
65 | ″ | ″ | relevant renal artery stenosis |
66 | ″ | ″ | renal artery stenosis |
67 | ″ | ″ | renal failure |
68 | ″ | ″ | restenosis rate |
69 | ″ | ″ | revascularization |
70 | ″ | ″ | secondary hypertension |
71 | ″ | ″ | stenosis |
72 | ″ | ″ | stent angioplasty |
73 | ″ | ″ | stent restenosis rate |
74 | ″ | ″ | stents |
75 | ″ | ″ | study protocol |
76 | ″ | ″ | trials |
77 | ″ | ″ | ventricular hypertrophy |
78 | ″ | schema:name | Renal artery stenosis |
79 | ″ | schema:pagination | 90-98 |
80 | ″ | schema:productId | N5206808052204a22b814cfeb3253c3fe |
81 | ″ | ″ | Nc718f29e38984911b63851e208ff3aac |
82 | ″ | ″ | Nfb952ed0d7374a37b7ff89f0f8d34d5c |
83 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1025547914 |
84 | ″ | ″ | https://doi.org/10.1007/s11936-007-0002-9 |
85 | ″ | schema:sdDatePublished | 2022-05-10T09:55 |
86 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
87 | ″ | schema:sdPublisher | N268a9c1e9f62442b9b9d000a3313859a |
88 | ″ | schema:url | https://doi.org/10.1007/s11936-007-0002-9 |
89 | ″ | sgo:license | sg:explorer/license/ |
90 | ″ | sgo:sdDataset | articles |
91 | ″ | rdf:type | schema:ScholarlyArticle |
92 | N268a9c1e9f62442b9b9d000a3313859a | schema:name | Springer Nature - SN SciGraph project |
93 | ″ | rdf:type | schema:Organization |
94 | N3fb599378c214e3eaf6b76cf194e5013 | schema:issueNumber | 2 |
95 | ″ | rdf:type | schema:PublicationIssue |
96 | N5206808052204a22b814cfeb3253c3fe | schema:name | pubmed_id |
97 | ″ | schema:value | 17484811 |
98 | ″ | rdf:type | schema:PropertyValue |
99 | Nbd779649f24c4f2ba90ae808bee468b6 | rdf:first | sg:person.01306206724.74 |
100 | ″ | rdf:rest | rdf:nil |
101 | Nc718f29e38984911b63851e208ff3aac | schema:name | doi |
102 | ″ | schema:value | 10.1007/s11936-007-0002-9 |
103 | ″ | rdf:type | schema:PropertyValue |
104 | Nf21a054ddd5d44529fa24a72a7ec0c61 | schema:volumeNumber | 9 |
105 | ″ | rdf:type | schema:PublicationVolume |
106 | Nfb952ed0d7374a37b7ff89f0f8d34d5c | schema:name | dimensions_id |
107 | ″ | schema:value | pub.1025547914 |
108 | ″ | rdf:type | schema:PropertyValue |
109 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
110 | ″ | schema:name | Medical and Health Sciences |
111 | ″ | rdf:type | schema:DefinedTerm |
112 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
113 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
114 | ″ | rdf:type | schema:DefinedTerm |
115 | sg:journal.1119516 | schema:issn | 1092-8464 |
116 | ″ | ″ | 1534-3189 |
117 | ″ | schema:name | Current Treatment Options in Cardiovascular Medicine |
118 | ″ | schema:publisher | Springer Nature |
119 | ″ | rdf:type | schema:Periodical |
120 | sg:person.01306206724.74 | schema:affiliation | grid-institutes:grid.418466.9 |
121 | ″ | schema:familyName | Zeller |
122 | ″ | schema:givenName | Thomas |
123 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306206724.74 |
124 | ″ | rdf:type | schema:Person |
125 | sg:pub.10.1007/s003300050707 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1039905631 |
126 | ″ | ″ | https://doi.org/10.1007/s003300050707 |
127 | ″ | rdf:type | schema:CreativeWork |
128 | sg:pub.10.1038/sj.jhh.1000599 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1018663291 |
129 | ″ | ″ | https://doi.org/10.1038/sj.jhh.1000599 |
130 | ″ | rdf:type | schema:CreativeWork |
131 | sg:pub.10.1038/sj.jhh.1001641 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1017671862 |
132 | ″ | ″ | https://doi.org/10.1038/sj.jhh.1001641 |
133 | ″ | rdf:type | schema:CreativeWork |
134 | grid-institutes:grid.418466.9 | schema:alternateName | Abteilung Angiologie, Herz-Zentrum Bad Krozingen, Südring 15, D-79189, Bad Krozingen, Germany |
135 | ″ | schema:name | Abteilung Angiologie, Herz-Zentrum Bad Krozingen, Südring 15, D-79189, Bad Krozingen, Germany |
136 | ″ | rdf:type | schema:Organization |